Search research articles
Contact Us
Filters
Showing results (91-100 of 182) with videos related to
Page
of 19
Sort By:
Plos One
|
June 16, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
Jeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, et al.
Endocrine-Related Cancer
|
May 15, 2023
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
Jennifer R Eads, Thorvardur R Halfdanarson, Tim Asmis, et al.
Oncotarget
|
October 4, 2014
Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity
Suganthi Chittaranjan, Susanna Chan, Cindy Yang, et al.
Pancreas
|
September 29, 2020
Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors
Jennifer R Eads, Diane Reidy-Lagunes, Heloisa P Soares, et al.
Cancer Research
|
September 3, 2009
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma
Yujin Hoshida, Sebastian M B Nijman, Masahiro Kobayashi, et al.
Nature Communications
|
May 3, 2019
Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors
Shiekh Tanveer Ahmad, Alexandra D Rogers, Myra J Chen, et al.
Cancer Research
|
July 2, 2015
RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors
Xuesong Zhao, Tatyana Ponomaryov, Kimberly J Ornell, et al.
Investigational New Drugs
|
April 10, 2013
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients
Douglas A Rubinson, Howard S Hochster, David P Ryan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 26, 2011
Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex
June Goto, Delia M Talos, Peter Klein, et al.
The Oncologist
|
August 3, 2021
Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review
David L Chan, Emily K Bergsland, Jennifer A Chan, et al.
Page
of 19
Search research articles
Search
Showing results (91-100 of 182) with videos related to
Sort By:
Page
of 19
Plos One
|
June 16, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
Jeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, et al.
Endocrine-Related Cancer
|
May 15, 2023
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
Jennifer R Eads, Thorvardur R Halfdanarson, Tim Asmis, et al.
Oncotarget
|
October 4, 2014
Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity
Suganthi Chittaranjan, Susanna Chan, Cindy Yang, et al.
Pancreas
|
September 29, 2020
Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors
Jennifer R Eads, Diane Reidy-Lagunes, Heloisa P Soares, et al.
Cancer Research
|
September 3, 2009
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma
Yujin Hoshida, Sebastian M B Nijman, Masahiro Kobayashi, et al.
Nature Communications
|
May 3, 2019
Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors
Shiekh Tanveer Ahmad, Alexandra D Rogers, Myra J Chen, et al.
Cancer Research
|
July 2, 2015
RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors
Xuesong Zhao, Tatyana Ponomaryov, Kimberly J Ornell, et al.
Investigational New Drugs
|
April 10, 2013
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients
Douglas A Rubinson, Howard S Hochster, David P Ryan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 26, 2011
Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex
June Goto, Delia M Talos, Peter Klein, et al.
The Oncologist
|
August 3, 2021
Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review
David L Chan, Emily K Bergsland, Jennifer A Chan, et al.
Page
of 19